185 related articles for article (PubMed ID: 30969023)
1. Circulating PD-1 (+) cells may participate in immune evasion in peripheral T-cell lymphoma and chidamide enhance antitumor activity of PD-1 (+) cells.
Zhang W; Shen H; Zhang Y; Wang W; Hu S; Zou D; Zhou D
Cancer Med; 2019 May; 8(5):2104-2113. PubMed ID: 30969023
[TBL] [Abstract][Full Text] [Related]
2. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
Shi Y; Jia B; Xu W; Li W; Liu T; Liu P; Zhao W; Zhang H; Sun X; Yang H; Zhang X; Jin J; Jin Z; Li Z; Qiu L; Dong M; Huang X; Luo Y; Wang X; Wang X; Wu J; Xu J; Yi P; Zhou J; He H; Liu L; Shen J; Tang X; Wang J; Yang J; Zeng Q; Zhang Z; Cai Z; Chen X; Ding K; Hou M; Huang H; Li X; Liang R; Liu Q; Song Y; Su H; Gao Y; Liu L; Luo J; Su L; Sun Z; Tan H; Wang H; Wang J; Wang S; Zhang H; Zhang X; Zhou D; Bai O; Wu G; Zhang L; Zhang Y
J Hematol Oncol; 2017 Mar; 10(1):69. PubMed ID: 28298231
[TBL] [Abstract][Full Text] [Related]
3. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.
Que Y; Zhang XL; Liu ZX; Zhao JJ; Pan QZ; Wen XZ; Xiao W; Xu BS; Hong DC; Guo TH; Shen LJ; Fan WJ; Chen HY; Weng DS; Xu HR; Zhou PH; Zhang YZ; Niu XH; Zhang X
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637599
[TBL] [Abstract][Full Text] [Related]
4. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Chemotherapy Combined With Chidamide Versus Chemotherapy in the Frontline Treatment for Peripheral T-Cell Lymphoma.
Wang J; Su N; Fang Y; Ma S; Zhang Y; Cai J; Zou Q; Tian X; Xia Y; Liu P; Li Z; Huang H; Huang H; Cai Q
Front Immunol; 2022; 13():835103. PubMed ID: 35185926
[TBL] [Abstract][Full Text] [Related]
6. Comparison of chidamide-contained treatment modalities versus chemotherapy in the second-line treatment for relapsed or refractory peripheral T-cell lymphoma.
Wang J; Fang Y; Ma S; Su N; Zhang Y; Huang H; Li Z; Huang H; Tian X; Cai J; Xia Y; Liu P; Cai Q
Leuk Res; 2021 Dec; 111():106705. PubMed ID: 34534908
[TBL] [Abstract][Full Text] [Related]
7. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
Ning ZQ; Li ZB; Newman MJ; Shan S; Wang XH; Pan DS; Zhang J; Dong M; Du X; Lu XP
Cancer Chemother Pharmacol; 2012 Apr; 69(4):901-9. PubMed ID: 22080169
[TBL] [Abstract][Full Text] [Related]
8. The combination of brentuximab vedotin and chidamide synergistically suppresses the proliferation of T-cell lymphoma cells through the enhancement of apoptosis.
Tonozuka Y; Tanaka H; Nomura K; Sakaguchi K; Soeda J; Kakimoto Y
Cancer Chemother Pharmacol; 2024 Feb; 93(2):137-149. PubMed ID: 37921901
[TBL] [Abstract][Full Text] [Related]
9. A Novel Mechanism of Action of Histone Deacetylase Inhibitor Chidamide: Enhancing the Chemotaxis Function of Circulating PD-1(+) Cells From Patients With PTCL.
Wei C; Hu S; Luo M; Chen C; Wang W; Zhang W; Zhou D
Front Oncol; 2021; 11():682436. PubMed ID: 34141623
[TBL] [Abstract][Full Text] [Related]
10. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.
Ji MM; Huang YH; Huang JY; Wang ZF; Fu D; Liu H; Liu F; Leboeuf C; Wang L; Ye J; Lu YM; Janin A; Cheng S; Zhao WL
Haematologica; 2018 Apr; 103(4):679-687. PubMed ID: 29305415
[TBL] [Abstract][Full Text] [Related]
11. Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma.
Zhang H; Dong L; Chen Q; Kong L; Meng B; Wang H; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X
Leuk Res; 2017 May; 56():29-35. PubMed ID: 28171799
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified.
Kim S; Kwon D; Koh J; Nam SJ; Kim YA; Kim TM; Kim CW; Jeon YK
Virchows Arch; 2020 Jul; 477(1):131-142. PubMed ID: 32170448
[TBL] [Abstract][Full Text] [Related]
13. Chidamide tablets: HDAC inhibition to treat lymphoma.
Xu Y; Zhang P; Liu Y
Drugs Today (Barc); 2017 Mar; 53(3):167-176. PubMed ID: 28447074
[TBL] [Abstract][Full Text] [Related]
14. Development of new agents for peripheral T-cell lymphoma.
Ito Y; Makita S; Tobinai K
Expert Opin Biol Ther; 2019 Mar; 19(3):197-209. PubMed ID: 30658046
[TBL] [Abstract][Full Text] [Related]
15. [Effect of HDAC Inhibitor Chidamide on PD-L1 Expression in Peripheral T-Cell Lymphoma].
Yan MM; Li ZX; Chen C; Zhang W; Zhou DB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1741-1745. PubMed ID: 36476897
[TBL] [Abstract][Full Text] [Related]
16. Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.
Zhang X; Liu L; Zhou S; Zhao K; Song Z; Hu G; Zhang T; Li Y; Qiu L; Li L; Qian Z; Meng B; Pan Y; Ren X; Wang X; Zhang H; Fu K
Hematol Oncol; 2019 Aug; 37(3):270-276. PubMed ID: 31074879
[TBL] [Abstract][Full Text] [Related]
17. Chidamide triggers BTG1-mediated autophagy and reverses the chemotherapy resistance in the relapsed/refractory B-cell lymphoma.
Xue K; Wu JC; Li XY; Li R; Zhang QL; Chang JJ; Liu YZ; Xu CH; Zhang JY; Sun XJ; Gu JJ; Guo WJ; Wang L
Cell Death Dis; 2021 Oct; 12(10):900. PubMed ID: 34599153
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of chidamide on the growth of human adenoid cystic carcinoma cells.
Yang S; Nan P; Li C; Lin F; Li H; Wang T; Zhou C; Zhang X; Meng X; Qian H; Wang H; Dong M
Biomed Pharmacother; 2018 Mar; 99():608-614. PubMed ID: 29710459
[TBL] [Abstract][Full Text] [Related]
19. PD-1 blockade combined with decitabine to treat refractory peripheral T-cell lymphoma not otherwise specified: A case report and review of literature.
Han X; Liu X; Zhang C; Wen Q; Zhang X
J Cancer Res Ther; 2023 Dec; 19(6):1680-1684. PubMed ID: 38156938
[TBL] [Abstract][Full Text] [Related]
20. Low-dose chidamide restores immune tolerance in ITP in mice and humans.
Zhao HY; Ma YH; Li DQ; Sun T; Li LZ; Li P; Liu XG; Zhou H; Hou Y; Liu Y; Han PP; Zhao YJ; Jing FM; Peng J; Hou M
Blood; 2019 Feb; 133(7):730-742. PubMed ID: 30552097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
